Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conmana and Thalidomide in EGFR-mutant NSCLC
NCT02778893Phase 4Unknown
- Sponsor
- Henan Provincial People's Hospital
- Start
- Mar 2016
- Primary completion
- Mar 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of icotinib and thalidomide in non-small cell lung cancer (NSCLC), sponsored by Henan Provincial People's Hospital. Primary endpoints: Progression-Free Survival Rate at 5 years, Overall Survival and 2 more. Status: unknown.
02
Drugs
icotinibthalidomide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02778893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02778893.